Composition with function of promoting filamentin expression, skin care preparation and application

Abstract

The embodiment of the invention provides a composition with a function of promoting fibroin expression, a skin care preparation and application. The composition and the skin care preparation can be used for promoting fibroin expression. The invention relates to a composition with a function of promoting the expression of filamentin. And a compound A; the compound A is selected from a compound as shown in a formula (I) or a formula (II).

Description

Technical Field

[0001] The present invention relates to the technical field of filaggrin expression, and in particular to a composition, a skin care preparation and uses thereof that can promote filaggrin expression. Background Art

[0002] The epidermis, which mitigates external irritation and controls the loss of body components such as water, is composed of four consecutive layers, starting with the basal layer, the spinous layer, the granular layer, and the stratum corneum. The majority of cells in each layer are keratinocytes that differentiate from the basal layer.

[0003] The keratinocyte that splits, proliferates can be further differentiated and become keratinocyte in the follow-up of basal layer, form the stratum corneum that is made up of the keratin fiber with firm cross-linking bond, finally come off from stratum corneum as dirt.The stratum corneum is present in the outermost layer of skin, plays a role as the physical barrier for the stimulation from the outside.In order to make skin have this barrier function, usually with the cycle of 4 weeks, repeat from producing keratinocyte in basal layer starting to it becoming dirt and peeling off till circulation (keratinization), carry out the metabolism of epidermis.

[0004] However, when the skin is affected by external factors such as ultraviolet rays, strong air dryness, excessive skin washing, smoking, or with age, the activity and proliferation capacity of epidermal cells will decrease, and the turnover speed of the epidermis will be delayed. This will cause incomplete differentiation such as thinning of the epidermis or thickening of the stratum corneum. This will in turn lead to a decrease in the skin's moisturizing function or elasticity, abnormal exfoliation of the keratin, and more likely to cause skin aging, and changes such as wrinkles, dullness, loss of texture, and reduced elasticity.

[0005] Filaggrin (FLG) is a filamentous protein that binds to keratin fibers in epithelial cells. During the terminal differentiation of epidermal cells, 10 to 12 filaggrin units are formed by post-translational hydrolysis of a large profilaggrin precursor protein.

[0006] Filaggrin is crucial for regulating epidermal homeostasis. Increasing filaggrin expression helps strengthen the binding of stratum corneum cells, making the skin tougher and more resistant to the external environment. Filaggrin is gradually degraded into natural moisturizing factors (NMFs) such as amino acids, lactic acid, and urea in the stratum corneum. Increasing filaggrin expression means more NMF production, thereby improving the skin's ability to retain moisture. Filaggrin helps maintain the integrity of the skin barrier, reduces transepidermal water loss (TEWL), and maintains skin moisture balance.

[0007] However, there are still few studies on promoting the expression of filaggrin, so it is an issue that needs to be addressed. Summary of the Invention

[0008] One purpose of the embodiments of the present application is to solve at least one of the problems in the above background and provide corresponding beneficial effects.

[0009] Another object of the embodiments of the present application is to provide a composition, a skin care preparation and a use thereof that have the function of promoting the expression of filaggrin, so as to solve the problem of how to promote the expression of filaggrin.

[0010] The embodiments of the present application mainly achieve the above objectives through the following technical solutions.

[0011] In a first aspect, the present invention provides a composition having a filaggrin expression function, comprising:

[0012] Phytol; and

[0013] Compound A; Compound A is selected from the compounds represented by formula (I) or formula (II);

[0014] Formula (I):

[0015] Formula (II):

[0016] In some technical solutions, in the composition having the function of expressing filaggrin,

[0017] The compound A is selected from the compounds represented by formula (I), and the mass ratio of the compound represented by formula (I) to phytol is 6:(4-9).

[0018] In some technical solutions, in the composition having the function of expressing filaggrin,

[0019] The compound A is selected from the compounds represented by formula (II), and the mass ratio of the compound represented by formula (II) to phytol is 12:(5-30).

[0020] In a second aspect, an embodiment of the present application provides a skin care preparation, comprising the composition having the function of promoting the expression of filaggrin described in the first aspect.

[0021] In a third aspect, an embodiment of the present application provides a use of the composition having the function of promoting filaggrin expression as described in the first aspect in preparing a skin care preparation.

[0022] In a fourth aspect, an embodiment of the present application provides a use of phytol and compound A in preparing a composition having the function of promoting filaggrin expression, wherein compound A is selected from the compounds represented by formula (I) or formula (II);

[0023] Formula (I):

[0024] Formula (II):

[0025] According to the use of the fourth aspect, in some technical solutions, the composition is used for skin care.

[0026] According to the use of the fourth aspect, in some technical solutions, compound A is selected from the compound represented by formula (I), and the mass ratio of the compound represented by formula (I) to phytol is 6: (4 to 9).

[0027] According to the use of the fourth aspect, in some technical solutions, compound A is selected from the compound represented by formula (II), and the mass ratio of the compound represented by formula (II) to phytol is 12: (5-30).

[0028] The beneficial effects of the embodiments of the present invention include:

[0029] 1. In some embodiments, the composition provided in the embodiments of the present application comprises phytol and compound A, wherein compound A is selected from the compounds represented by formula (I) or formula (II); the compound of formula (I) or formula (II) in the composition, combined with phytol, can play a synergistic role in promoting the expression of FLG.

[0030] 2. In some embodiments, the present application provides a use of the composition having the function of promoting FLG expression as described in the first aspect in preparing a skin care preparation.

[0031] 3. In some embodiments, the present application provides a use of phytol and compound A in preparing a composition having the function of promoting FLG expression, wherein compound A is selected from the compounds represented by formula (I) or formula (II). BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 A schematic structural diagram of the compound of formula (I) in the examples of this application;

[0033] Figure 2 A schematic structural diagram of the compound of formula (II) in the examples of this application;

[0034] Figure 3 This is a schematic diagram of a hydrogen nuclear magnetic spectrum of the compound represented by formula (I) in the examples of this application;

[0035] Figure 4This is a schematic diagram of a carbon NMR spectrum of the compound represented by formula (I) in the examples of this application;

[0036] Figure 5 A mass spectrum of the compound represented by formula (I) in the examples of this application;

[0037] Figure 6 This is a schematic diagram of a hydrogen nuclear magnetic spectrum of the compound represented by formula (II) in the examples of this application;

[0038] Figure 7 This is a carbon NMR spectrum diagram of the compound represented by formula (II) in the examples of this application;

[0039] Figure 8 A mass spectrum of the compound represented by formula (II) in the examples of this application;

[0040] Figure 9 This is a schematic diagram of the relative expression levels of mRNA corresponding to each group of samples in Experimental Example 3;

[0041] Figure 10 This is a schematic diagram of the relative expression level of mRNA corresponding to each group of samples in Experimental Example 4. DETAILED DESCRIPTION

[0042] The present invention will be described in further detail below in conjunction with the accompanying drawings so that those skilled in the art can implement the invention with reference to the description.

[0043] The terms "first," "second," etc., in the embodiments of this application are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of technical features indicated. Therefore, a feature defined as "first," "second," etc. may explicitly or implicitly include at least one of such features.

[0044] Furthermore, the terms "comprises," "comprising," "including," "having," and any variations thereof are intended to cover non-exclusive inclusions. For example, a process, method, system, product, or apparatus comprising a series of steps or elements is not limited to the listed steps or elements, but may optionally include steps or elements not listed, or may optionally include other steps or elements inherent to the process, method, product, or apparatus.

[0045] The term "DMEM" refers to a culture medium, whose full English name is Dulbecco's Modified Eagle's Medium.

[0046] In addition to the above, it is still important to emphasize that references to "embodiments" herein mean that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of such phrases in various locations in the specification does not necessarily refer to the same embodiment, nor does it necessarily refer to independent or alternative embodiments that are mutually exclusive of other embodiments. It is understood, both explicitly and implicitly, by those skilled in the art that the embodiments described herein may be combined with other embodiments.

[0047] <Composition>

[0048] The present invention provides a composition having the function of promoting FLG expression, comprising:

[0049] Phytol; and

[0050] Compound A; Compound A is selected from the compounds represented by formula (I) or formula (II);

[0051] Formula (I): The structure of formula (I) can also be found in Figure 1 ;

[0052] Formula (II): The structure of formula (II) can also be found in Figure 2 .

[0053] The composition provided in the examples of the present application, which combines the compound of formula (I) or the compound of formula (II) with phytol, can play a synergistic role in promoting the expression of FLG.

[0054] In some embodiments, compound A is selected from the compounds represented by formula (I), and the mass ratio of the compound represented by formula (I) to phytol is 12:(8-18), that is, 6:(4-9).

[0055] In some embodiments, compound A is selected from the compound represented by formula (I), the concentration of the compound of formula (I) is 12 μg / mL, and the concentration of phytol is 8-18 μg / mL; optionally, the concentration of phytol is 18 μg / mL; optionally, the concentration of phytol is 8 μg / mL.

[0056] In some embodiments, compound A is selected from the compounds represented by formula (II), and the mass ratio of the compound represented by formula (II) to phytol is 12:(5-30).

[0057] In some embodiments, compound A is selected from the compound represented by formula (II), the concentration of the compound of formula (II) is 12 μg / mL, and the concentration of phytol is 5-30 μg / mL; optionally, the concentration of phytol is 5 μg / mL; optionally, the concentration of phytol is 30 μg / mL.

[0058] In some embodiments, the composition includes a solvent for dissolving phytol and Compound A.

[0059] In some embodiments, the solvent is a cosmetically acceptable solvent, for example, one or more of dibutyl adipate, isononyl isononanoate, pentaerythritol tetra(ethylhexanoate), caprylic / capric triglyceride, cetyl ethylhexanoate, diisostearyl malate, and octyldodecanol can be selected.

[0060] In some embodiments, the composition includes: a cosmetically acceptable adjuvant. Optionally, the adjuvant is selected from one or more of surfactants and / or emulsifiers, preservatives, buffers, chelating agents, denaturants, opacifiers, pH adjusters, reducing agents and stabilizers, thickeners, gelling agents, film-forming polymers, fillers, matting agents, glossing agents, pigments, dyes, fragrances, and mixtures thereof.

[0061] In certain embodiments, the composition can be manufactured in the form of a cream, liquid, gel, powder, block, paste-like solid, wax-based, freeze-dried, spray, aerosol, or matrix.

[0062] Optionally, the cream is in the form of milk, ointment, cream, honey, fat, milk, emulsion, milk or milk solution.

[0063] Optionally, the liquid form is further in the form of dew, liquid, water, oil or oil-water separation.

[0064] Optionally, the gel form can be further in the form of jelly or glue.

[0065] Optionally, the powder form can be further in the form of loose powder or granules.

[0066] Alternatively, the bulk form may be further in the form of bulk powder, bulk solid, and the like.

[0067] Optionally, the wax base uses wax as the main base material.

[0068] Optionally, the lyophilized form is further in the form of lyophilized powder, lyophilized tablets, etc.

[0069] Optionally, the spray contains no propellant.

[0070] Optionally, the aerosol contains a propellant.

[0071] Optionally, the substrate is in the form of a sticker, a film, etc.

[0072] In certain embodiments, the composition can be topically applied to the hair, body hair, trunk, head, face, eyes, lips, hands, feet, skin all over the body, fingernails, nails, etc.

[0073] In some embodiments, the composition can be used to prepare a skin care formulation. The skin care formulation can function to protect the skin by promoting the expression of FLG.

[0074] In some embodiments, the skin care formulation is a topical skin care formulation.

[0075] In some embodiments, the composition is a skin care formulation, and the sum of the mass fraction of phytol and Compound A in the composition is 0.0001-10%.

[0076] It should be noted that the compound of formula (I) can be obtained by direct purchase, and in some embodiments, can also be synthesized by the method shown in steps S11-S13:

[0077] Step S11, add 466 mg of ferulic acid (3-methoxy-4-hydroxycinnamic acid) to a 50 mL round-bottom flask, dissolve with 10 mL of dichloromethane, then add 1.4 mL of triethylamine, cool the resulting reaction solution to 0-5°C with an ice water bath, slowly add 900 mg of tert-butyldimethylsilyl chloride, and stir at room temperature for 4 hours. After the reaction is completed, quench the reaction with 25 mL of ice water, extract the aqueous layer with dichloromethane (25 mL x 3), combine the organic layers, dry the organic layer with anhydrous sodium sulfate, filter, and vacuum concentrate to obtain the crude product. Dissolve the crude product with 20 mL of tetrahydrofuran and 2 mL of water, add 200 mg of anhydrous potassium carbonate, and stir the reaction at room temperature for 6 hours. After the reaction is completed, add 25 mL of water and extract the aqueous layer with ethyl acetate (25 mL x 3), combine the organic layers, vacuum concentrate, and recrystallize with petroleum ether to obtain the first intermediate.

[0078] Step S12, add 308 mg of the first intermediate, 343 mg of retinol, 288 mg of EDCI, and 12 mg of DMAP to a 50 mL brown round-bottom flask, dissolve with 5 mL of tetrahydrofuran, and finally add 270 μL of TEA, stir the reaction at room temperature for 12 hours. After the reaction is completed, vacuum concentrate the reaction solution, add 25 mL of water, extract the aqueous layer with ethyl acetate (25 mL x 3), combine the organic layers, dry the organic layer with anhydrous sodium sulfate, filter, vacuum concentrate to obtain the crude product, and purify by silica gel column chromatography (petroleum ether: ethyl acetate = 20:1 as eluent) to obtain the second intermediate.

[0079] Step S13, add 384 mg of the second intermediate to a 50 mL brown round-bottom flask, dissolve with 8 mL of tetrahydrofuran, cool to 0-5°C with an ice water bath, slowly add 600 μL of tetrabutylammonium fluoride dropwise, and stir in the ice bath for 10 minutes. Vacuum concentrate to obtain the crude product, and purify by silica gel column chromatography (petroleum ether: ethyl acetate = 5:1 as eluent) to obtain the compound of formula (I).

[0080] In some embodiments, the hydrogen spectrum nuclear magnetic data of the compound of formula (I) is measured as follows: Figure 3 P1175 in Table 1 (the number of the compound of formula (I) in Table 1) is as follows: Figure 3

[0081] 1 H NMR (500 MHz, CDC13) δ 7.62 (d, J = 15.9 Hz, 1H), 7.07 (dd, J = 8.3, 2.0 Hz, 1H), 7.02 (d, J = 1.9 Hz, 1H), 6.91 (d, J = 8.2 Hz, 1H), 6.65 (dd, J = 15.1, 11.2 Hz, 1H), 6.30 (d, J = 15.9 Hz, 2H), 6.22 - 6.06 (m, 3H), 5.90 (s, 1H), 5.69 (t, J = 7.2 Hz, 1H), 4.86 (d, J = 7.2 Hz, 2H), 3.92 (s, 3H), 2.01 (t, J = 6.3 Hz, 2H), 1.96 (s, 3H), 1.93 (s, 3H), 1.71 (s, 3H), 1.63 - 1.57 (m, 2H), 1.49 - 1.44 (m, 2H), 1.02 (s, 6H).

[0082] In some embodiments, the carbon spectrum nuclear magnetic data of the compound of formula (I) is measured as shown in Table 2, and the chemical formula is C Figure 4

[0083] 13 C NMR (101 MHz, CDC13) δ 167.18, 147.98, 146.76, 144.97, 139.15, 137.77, 137.55, 136.53, 135.82, 129.93, 129.30, 126.93, 125.74, 124.61, 123.05, 115.28, 114.72, 109.31, 61.20, 55.86, 39.57, 34.21, 33.02, 28.91, 21.68, 19.22, 12.75, 12.69.

[0084] The hydrogen spectrum nuclear magnetic data is measured by a nuclear magnetic resonance spectrometer (model: JNM-ECZ500R / S1, manufacturer: JEOL, Japan). The carbon spectrum nuclear magnetic data is measured by a nuclear magnetic resonance spectrometer (model: Bruker AV NEO 400, manufacturer: Bruker, USA).

[0085] In some embodiments, the mass spectrum data of the compound of formula (I) is measured as shown in Table 3, and the chemical formula is C Figure 5 30 H 38 O4, and the molecular weight is 461.26973. ​​​

[0086] The compound of formula (II) can be directly purchased, or in some embodiments, can be synthesized by the method shown in the following steps S21 to S27:

[0087] Step S21: 3-(Benzo[d][1,3]dioxolane-5-yl)acrylic acid, bakuchiol, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 4-dimethylaminopyridine, triethylamine, and tetrahydrofuran are mixed and stirred at room temperature to obtain a mixture.

[0088] In practice, 4.5 g (22.6 mmol, 1.5 equiv) of 3-(benzo[d][1,3]dioxolane-5-yl)acrylic acid, 4.5 g (15 mmol, 1 equiv) of bakuchiol, 5.76 g (30 mmol, 2 equiv) of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 180 mg (1.5 mmol, 0.1 equiv) of 4-dimethylaminopyridine, 4.8 mL (37.6 mmol, 2.5 equiv) of triethylamine and 80 mL of tetrahydrofuran can be added to a 200 mL reactor and stirred at room temperature for 12 hours to obtain a mixture.

[0089] Step S22: performing a first reduced-pressure concentration on the mixture to obtain a first concentrate.

[0090] The mixture is concentrated under reduced pressure at a temperature of 40±5° C. to obtain a first concentrate.

[0091] Step S23, extracting the first concentrate dissolved in water with ethyl acetate for a target number of times, and collecting the organic layer.

[0092] In practice, first, 200 mL of water was added to the first concentrate to dissolve the first concentrate in water. Then, the aqueous layer of the first concentrate after dissolution was extracted with ethyl acetate (200 mL x 3) a target number of times, where the target number of times is ≥ 1. Finally, the organic layers were combined.

[0093] Step S24: performing a second reduced-pressure concentration on the dried organic layer to obtain a second concentrate.

[0094] In practice, first, 10 g of anhydrous sodium sulfate was added to the organic layer to dry the organic layer and filter it to obtain the dried organic layer. Then, the dried organic layer was concentrated under reduced pressure at 40±5° C. to obtain a second concentrate (crude oily product).

[0095] Step S25: adding petroleum ether to the second concentrate and performing a third concentration under reduced pressure to obtain a first solid.

[0096] In practice, 60 mL of petroleum ether was added to the second concentrate, and the mixture was concentrated under reduced pressure at 40±5° C. to obtain a first solid (yellow solid).

[0097] Step S26: mixing the mixed liquid with the first solid, beating and filtering to obtain a filter cake.

[0098] The mixed liquid includes petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 50:1.

[0099] In practice, 200 mL of a mixture of petroleum ether and ethyl acetate was mixed with the first solid and slurried for 30 minutes, and filtered using a Buchner funnel to obtain a filter cake.

[0100] Step S27: vacuum-dry the filter cake to obtain the compound of formula (II).

[0101] In practice, the filter cake is vacuum dried at 40±5° C. to obtain the compound of formula (II).

[0102] In some embodiments, the H NMR data of the compound of formula (II) is measured as follows: Figure 6 As shown in ( Figure 6 P1161 in the formula (II) is the number of the compound), the data are as follows:

[0103] 1 H NMR (500MHz, CDCl3) δ7.77(d,J=15.9Hz,1H),7.39(d,J=8.6Hz,2H),7.10(d,J=2.0Hz,1H),7.09(q,J=2 .8,2.3Hz,2H),7.06(dd,J=8.1,1.7Hz,1H),6.84(d,J=8.0Hz,1H),6.44(d,J=15.9Hz,1H),6.32(d,J=16 .2Hz,1H),6.18(d,J=16.3Hz,1H),6.03(s,2H),5.89(dd,J=17.5,10.7Hz,1H),5.11(tt,J=7.1,1.4Hz,1 H),5.08–4.99(m,2H),1.96(q,J=7.5Hz,2H),1.68(s,3H),1.59(s,3H),1.54–1.48(m,2H),1.21(s,3H).

[0104] In some embodiments, the carbon spectroscopy nuclear magnetic resonance data of the compound of formula (II) is measured as follows Figure 7 As shown, the data is as follows:

[0105] 13C NMR (101MHz, CDCl3) δ165.59,149.95,149.71,148.42,146.20,145.65,138.07,135.56,131.33,128.60,126.94,12 6.32,124.86,124.68,121.59,115.09,112.08,108.60,106.56,101.62,42.62,41.19,25.66,23.27,23.19,17.62.

[0106] The H NMR data were obtained using a nuclear magnetic resonance spectrometer (model: JNM-ECZ500R / S1, manufacturer: JEOL, Japan), and the C NMR data were obtained using a nuclear magnetic resonance spectrometer (model: Bruker AV NEO 400, manufacturer: Bruker, USA).

[0107] In some embodiments, the mass spectrum of the compound of formula (II) is measured as follows Figure 8 As shown, the chemical formula is C 28 H 30 O4, molecular weight is 431.22.

[0108] <Purpose>

[0109] Based on the composition and technical effects described in the above embodiments, the present application also provides a method for preparing a composition having the function of promoting FLG expression by using phytol and compound A, wherein compound A is selected from the compound represented by formula (I) or formula (II);

[0110] Formula (I):

[0111] Formula (II):

[0112] It can be understood that the combination of compound A and phytol can play a synergistic role in promoting the expression of FLG, thereby enabling the composition having the function of promoting FLG expression to have the effect of promoting FLG expression.

[0113] In some embodiments, compound A is selected from the compounds represented by formula (I), and the mass ratio of the compound represented by formula (I) to phytol is 12:(8-18), that is, 6:(4-9).

[0114] In some embodiments, compound A is selected from the compound represented by formula (I), the concentration of the compound of formula (I) is 12 μg / mL, and the concentration of phytol is 8-18 μg / mL; optionally, the concentration of phytol is 18 μg / mL; optionally, the concentration of phytol is 8 μg / mL.

[0115] In some embodiments, compound A is selected from the compounds represented by formula (II), and the mass ratio of the compound represented by formula (II) to phytol is 12:(5-30).

[0116] In some embodiments, compound A is selected from the compound represented by formula (II), the concentration of the compound of formula (II) is 12 μg / mL, and the concentration of phytol is 5-30 μg / mL; optionally, the concentration of phytol is 5 μg / mL; optionally, the concentration of phytol is 30 μg / mL.

[0117] In some embodiments, the composition is a skin care formulation.

[0118] In some embodiments, the skin preparation is a topical skin care preparation.

[0119] <Experiment>

[0120] It should be noted that in the following Experimental Examples 1 to 4, when cell culture fluid is involved, it is prepared according to the following preparation method.

[0121] The cell culture medium was DMEM medium containing 10% FBS and 1% penicillin / streptomycin;

[0122] The cell culture medium is prepared as follows: fetal bovine serum (FBS), penicillin / streptomycin and DMEM culture medium are mixed to obtain a DMEM culture medium solution containing 10% FBS and 1% penicillin / streptomycin, wherein the volume fraction of FBS is 10% and the volume fraction of penicillin / streptomycin is 1%.

[0123] <Experimental Example 1>

[0124] Samples 1-1 to 1-49 were prepared and used to treat human immortalized keratinocytes. The survival rate of the cells treated with each sample was then detected using the CCK8 method (Cell Counting Kit-8 method).

[0125] The CCK8 method can be performed according to the experimental methods described in "Molecular Biology Experimental Techniques" or "Molecular Experimental Technique Guide" or "Cell Biology Experimental Course" or "Biochemistry and Molecular Biology Experiments".

[0126] In Experimental Example 1, the CCK8 method was performed according to the relevant method described in "Molecular Biology Experimental Techniques".

[0127] 1. Experimental samples

[0128] Sample 1-1:

[0129] Sample 1-1 is a solution containing the compound of formula (I), wherein the concentration of the compound of formula (I) is 50 μg / mL.

[0130] The preparation method of sample 1-1 is as follows: the compound of formula (I) and cell culture medium are mixed to obtain sample 1-1.

[0131] Sample 1-2 to Sample 1-6:

[0132] Samples 1-2 to 1-6 are basically the same as sample 1-1, except for the concentration of the compound of formula (I). Therefore, the preparation method can be implemented with reference to sample 1-1.

[0133] The concentration of the compound of formula (I) in sample 1-2 was 40 μg / mL;

[0134] The concentration of the compound of formula (I) in sample 1-3 was 30 μg / mL;

[0135] The concentration of the compound of formula (I) in sample 1-4 was 20 μg / mL;

[0136] The concentration of the compound of formula (I) in samples 1-5 was 10 μg / mL;

[0137] The concentration of the compound of formula (I) in Samples 1-6 was 5 μg / mL.

[0138] Samples 1-7:

[0139] Samples 1-7 are cell culture fluids.

[0140] Samples 1-8:

[0141] Sample 1-8 is a culture solution containing the compound of formula (I) and phytol, wherein the concentration of the compound of formula (I) is 50 μg / mL and the concentration of phytol is 1 μg / mL.

[0142] The preparation method of Sample 1-8 is as follows: the cell culture medium, the compound of formula (I) and phytol are mixed to obtain Sample 1-8.

[0143] Sample 1-9 to Sample 1-13:

[0144] Samples 1-9 to 1-13 are basically the same as sample 1-8, except for the concentration of the compound of formula (I). Therefore, the preparation method can be implemented with reference to sample 1-1.

[0145] The concentration of the compound of formula (I) in sample 1-9 was 40 μg / mL;

[0146] The concentration of the compound of formula (I) in sample 1-10 was 30 μg / mL;

[0147] The concentration of the compound of formula (I) in sample 1-11 was 20 μg / mL;

[0148] The concentration of the compound of formula (I) in sample 1-12 is 10 μg / mL.

[0149] The concentration of the compound of formula (I) in sample 1-13 is 5 μg / mL.

[0150] Sample 1-14:

[0151] Sample 1-14 is a phytol-containing culture solution, which does not contain the compound of formula (I) compared with sample 1-8. Sample 1-14 is prepared by mixing the cell culture solution and phytol.

[0152] Sample 1-15:

[0153] Sample 1-15 is basically the same as sample 1-8, except that the concentration of phytol is different, and thus the preparation method can be implemented by referring to sample 1-8.

[0154] The concentration of the compound of formula (I) in sample 1-15 is 50 μg / mL, and the concentration of phytol is 3 μg / mL.

[0155] Samples 1-16 to 1-20:

[0156] Samples 1-16 to 1-21 are basically the same as sample 1-15, except that the concentration of the compound of formula (I) is different, and thus the preparation method can be implemented by referring to sample 1-15.

[0157] The concentration of the compound of formula (I) in sample 1-16 is 40 μg / mL;

[0158] The concentration of the compound of formula (I) in sample 1-17 is 30 μg / mL;

[0159] The concentration of the compound of formula (I) in sample 1-18 is 20 μg / mL;

[0160] The concentration of the compound of formula (I) in sample 1-19 is 10 μg / mL;

[0161] The concentration of the compound of formula (I) in sample 1-20 is 5 μg / mL.

[0162] Sample 1-21:

[0163] It is basically the same as sample 1-14, except that the concentration of phytol is different, and thus the preparation method can be implemented by referring to sample 1-14.

[0164] The concentration of phytol in sample 1-21 is 3 μg / mL.

[0165] Sample 1-22:

[0166] Sample 1-22 is basically the same as sample 1-8, except for the concentration of phytol. Therefore, the preparation method can be implemented with reference to sample 1-8.

[0167] In sample 1-22, the concentration of the compound of formula (I) was 50 μg / mL, and the concentration of phytol was 5 μg / mL.

[0168] Sample 1-23 to Sample 1-20:

[0169] Samples 1-23 to 1-28 are basically the same as sample 1-22, except for the concentration of the compound of formula (I). Therefore, the preparation method can be implemented with reference to sample 1-15.

[0170] The concentration of the compound of formula (I) in sample 1-23 was 40 μg / mL;

[0171] The concentration of the compound of formula (I) in sample 1-24 was 30 μg / mL;

[0172] The concentration of the compound of formula (I) in sample 1-25 was 20 μg / mL;

[0173] The concentration of the compound of formula (I) in sample 1-26 was 10 μg / mL;

[0174] The concentration of the compound of formula (I) in sample 1-27 was 5 μg / mL.

[0175] Sample 1-28:

[0176] It is basically the same as sample 1-14, except for the concentration of phytol, so it can be configured with reference to sample 1-14.

[0177] The concentration of phytol in sample 1-28 was 5 μg / mL.

[0178] Sample 1-29:

[0179] Sample 1-29 is basically the same as sample 1-8, except for the concentration of phytol. Therefore, the preparation method can be implemented with reference to sample 1-8.

[0180] In sample 1-29, the concentration of the compound of formula (I) was 50 μg / mL, and the concentration of phytol was 10 μg / mL.

[0181] Sample 1-30 to Sample 1-35:

[0182] Samples 1-30 to 1-35 are basically the same as sample 1-29, except for the concentration of the compound of formula (I). Therefore, the preparation method can be implemented with reference to sample 1-29.

[0183] In sample 1-30, the concentration of the compound of formula (I) was 40 μg / mL, and the concentration of phytol was 10 μg / mL;

[0184] In sample 1-31, the concentration of the compound of formula (I) was 30 μg / mL, and the concentration of phytol was 10 μg / mL;

[0185] In sample 1-32, the concentration of the compound of formula (I) was 20 μg / mL, and the concentration of phytol was 10 μg / mL;

[0186] In sample 1-33, the concentration of the compound of formula (I) was 10 μg / mL, and the concentration of phytol was 10 μg / mL;

[0187] In sample 1-34, the concentration of the compound of formula (I) was 5 μg / mL, and the concentration of phytol was 10 μg / mL.

[0188] Sample 1-35:

[0189] It is basically the same as sample 1-14, except for the concentration of phytol, so it can be configured with reference to sample 1-14.

[0190] The concentration of phytol in sample 1-35 was 10 μg / mL.

[0191] Sample 1-36:

[0192] Sample 1-36 is basically the same as sample 1-8, except for the concentration of phytol. Therefore, the preparation method can be implemented with reference to sample 1-8.

[0193] In sample 1-36, the concentration of the compound of formula (I) was 50 μg / mL, and the concentration of phytol was 15 μg / mL.

[0194] Sample 1-37 to Sample 1-42:

[0195] Samples 1-37 to 1-42 are basically the same as sample 1-36, except for the concentration of the compound of formula (I). Therefore, the preparation method can be implemented with reference to sample 1-36.

[0196] In sample 1-37, the concentration of the compound of formula (I) was 40 μg / mL, and the concentration of phytol was 15 μg / mL;

[0197] In sample 1-38, the concentration of the compound of formula (I) was 30 μg / mL, and the concentration of phytol was 15 μg / mL;

[0198] In sample 1-39, the concentration of the compound of formula (I) was 20 μg / mL, and the concentration of phytol was 15 μg / mL;

[0199] The concentration of the compound of formula (I) in sample 1-40 is 10 μg / mL, and the concentration of phytol is 15 μg / mL.

[0200] The concentration of the compound of formula (I) in sample 1-41 is 5 μg / mL, and the concentration of phytol is 15 μg / mL.

[0201] Sample 1-42:

[0202] It is basically the same as sample 1-14, except that the concentration of phytol is different, so the configuration method can be implemented by referring to sample 1-14.

[0203] The concentration of phytol in sample 1-42 is 15 μg / mL.

[0204] Sample 1-43:

[0205] Sample 1-43, basically the same as sample 1-8, except that the concentration of phytol is different, so the configuration method can be implemented by referring to sample 1-8.

[0206] The concentration of the compound of formula (I) in sample 1-43 is 50 μg / mL, and the concentration of phytol is 20 μg / mL.

[0207] Sample 1-44~Sample 1-48:

[0208] Sample 1-44~Sample 1-48, basically the same as sample 1-43, except that the concentration of the compound of formula (I) is different, so the configuration method can be implemented by referring to sample 1-43.

[0209] The concentration of the compound of formula (I) in sample 1-44 is 40 μg / mL, and the concentration of phytol is 20 μg / mL;

[0210] The concentration of the compound of formula (I) in sample 1-45 is 30 μg / mL, and the concentration of phytol is 20 μg / mL;

[0211] The concentration of the compound of formula (I) in sample 1-46 is 20 μg / mL, and the concentration of phytol is 20 μg / mL;

[0212] The concentration of the compound of formula (I) in sample 1-47 is 10 μg / mL, and the concentration of phytol is 20 μg / mL;

[0213] The concentration of the compound of formula (I) in sample 1-48 is 5 μg / mL, and the concentration of phytol is 20 μg / mL.

[0214] Sample 1-49:

[0215] It is basically the same as sample 1-14, except that the concentration of phytol is different, so the configuration method can be implemented by referring to sample 1-14.

[0216] The concentration of phytol in sample 1-49 was 20 μg / mL.

[0217] 2. Experimental results:

[0218] The experimental results are shown in Table 1.

[0219] Table 1. Cell survival rate of Experimental Example 1

[0220]

[0221] According to the experimental results, when the concentration of phytol is 0-15 ug / mL and the concentration of the compound of formula (I) is 0-50 ug / mL, there is basically no adverse effect on human immortalized keratinocytes.

[0222] <Experimental Example 2>

[0223] Samples 2-1 to 2-36 were prepared and used to treat human immortalized keratinocytes. The survival rate of the cells treated with each sample was then determined using the CCK8 method (Cell Counting Kit-8 method).

[0224] The CCK8 method can be performed according to the experimental methods described in "Molecular Biology Experimental Techniques" or "Molecular Experimental Technique Guide" or "Cell Biology Experimental Course" or "Biochemistry and Molecular Biology Experiments".

[0225] In Experimental Example 2, the CCK8 method was performed according to the relevant method described in "Molecular Biology Experimental Techniques".

[0226] 1. Experimental samples

[0227] Sample 2-1:

[0228] Sample 2-1 is a culture solution containing the compound of formula (II), wherein the concentration of the compound of formula (II) is 50 μg / mL.

[0229] The preparation method of sample 2-1 is as follows: the cell culture medium and the compound of formula (II) are mixed to obtain sample 2-1.

[0230] Sample 2-2 to Sample 2-6:

[0231] Samples 2-2 to 2-6 are basically the same as sample 2-1, except for the concentration of the compound of formula (II). Therefore, the preparation method can be implemented with reference to sample 2-1.

[0232] The concentration of the compound of formula (II) in sample 2-2 was 25 μg / mL;

[0233] The concentration of the compound of formula (II) in sample 2-3 was 12 μg / mL;

[0234] The concentration of the compound of formula (II) in sample 2-4 was 6 μg / mL;

[0235] The concentration of the compound of formula (II) in sample 2-5 was 3 μg / mL.

[0236] Samples 2-6:

[0237] Sample 2-6 does not contain the compound of formula (II), that is, the concentration of the compound of formula (II) is 0; sample 2-6 is specifically a cell culture medium.

[0238] Samples 2-7:

[0239] Sample 2-7 is a culture solution containing the compound of formula (II) and phytol, wherein the concentration of the compound of formula (II) is 50 μg / mL and the concentration of phytol is 4 μg / mL.

[0240] The preparation method of sample 2-7 is as follows: the cell culture medium, the compound of formula (II) and phytol are mixed to obtain sample 2-1.

[0241] Sample 2-8 to Sample 2-11:

[0242] Samples 2-2 to 2-6 are basically the same as sample 2-7, except for the concentration of the compound of formula (II). Therefore, the preparation method can be implemented with reference to sample 2-7.

[0243] The concentration of the compound of formula (II) in sample 2-2 was 25 μg / mL;

[0244] The concentration of the compound of formula (II) in sample 2-3 was 12 μg / mL;

[0245] The concentration of the compound of formula (II) in sample 2-4 was 6 μg / mL;

[0246] The concentration of the compound of formula (II) in sample 2-5 was 3 μg / mL.

[0247] Sample 2-12:

[0248] Sample 2-12 is a culture solution containing phytol, wherein the concentration of phytol is 4 μg / mL. Compared with sample 2-7, it does not contain the compound of formula (II).

[0249] The preparation method of sample 2-12 is as follows: the cell culture medium and phytol are mixed to obtain sample 2-12.

[0250] Sample 2-13:

[0251] Sample 2-13 is substantially the same as Sample 2-7, except for the concentration of phytol. Therefore, the preparation method can be implemented with reference to Sample 2-7. In Sample 2-13, the concentration of the compound of formula (II) is 50 μg / mL, and the concentration of phytol is 8 μg / mL.

[0252] Samples 2-14 to 2-17:

[0253] Samples 2-14 to 2-17 are basically the same as sample 2-13, except for the concentration of the compound of formula (II). Therefore, the preparation method can be implemented with reference to sample 2-13.

[0254] The concentration of the compound of formula (II) in sample 2-14 was 25 μg / mL;

[0255] The concentration of the compound of formula (II) in sample 2-15 was 12 μg / mL;

[0256] The concentration of the compound of formula (II) in sample 2-16 was 6 μg / mL;

[0257] The concentration of the compound of formula (II) in sample 2-17 was 3 μg / mL.

[0258] Sample 2-18:

[0259] Sample 2-18 is essentially the same as Sample 2-12, except for the concentration of phytol. Therefore, the preparation can be based on Sample 2-12. The concentration of phytol in Sample 2-18 is 8 μg / mL.

[0260] Sample 2-19:

[0261] Sample 2-19 is basically the same as Sample 2-7, except for the concentration of phytol. Therefore, the preparation method can be implemented with reference to Sample 2-7. In Sample 2-19, the concentration of the compound of formula (II) is 50 μg / mL, and the concentration of phytol is 15 μg / mL.

[0262] Samples 2-20 to 2-23:

[0263] Samples 2-20 to 2-23 are basically the same as sample 2-13, except for the concentration of the compound of formula (II). Therefore, the preparation method can be implemented with reference to sample 2-13.

[0264] The concentration of the compound of formula (II) in sample 2-20 was 25 μg / mL;

[0265] The concentration of the compound of formula (II) in sample 2-21 was 12 μg / mL;

[0266] The concentration of the compound of formula (II) in sample 2-22 was 6 μg / mL;

[0267] The concentration of the compound of formula (II) in sample 2-23 was 3 μg / mL.

[0268] Sample 2-24:

[0269] Sample 2-24 is essentially the same as Sample 2-12, except for the concentration of phytol. Therefore, the preparation can be based on Sample 2-12. The concentration of phytol in Sample 2-24 is 15 μg / mL.

[0270] Sample 2-25:

[0271] Sample 2-25 is basically the same as Sample 2-7, except for the concentration of phytol. Therefore, the preparation method can be implemented with reference to Sample 2-7. In Sample 2-25, the concentration of the compound of formula (II) is 50 μg / mL, and the concentration of phytol is 30 μg / mL.

[0272] Samples 2-26 to 2-29:

[0273] Samples 2-26 to 2-29 are basically the same as sample 2-13, except for the concentration of the compound of formula (II). Therefore, the preparation method can be implemented with reference to sample 2-13.

[0274] The concentration of the compound of formula (II) in sample 2-26 was 25 μg / mL;

[0275] The concentration of the compound of formula (II) in sample 2-27 was 12 μg / mL;

[0276] The concentration of the compound of formula (II) in sample 2-28 was 6 μg / mL;

[0277] The concentration of the compound of formula (II) in sample 2-29 was 3 μg / mL.

[0278] Sample 2-30:

[0279] Sample 2-30 is essentially the same as Sample 2-12, except for the concentration of phytol. Therefore, the preparation can be based on Sample 2-12. The concentration of phytol in Sample 2-30 is 30 μg / mL.

[0280] Sample 2-31:

[0281] Sample 2-31 is basically the same as Sample 2-7, except for the concentration of phytol. Therefore, the preparation method can be implemented with reference to Sample 2-7. In Sample 2-31, the concentration of the compound of formula (II) is 50 μg / mL, and the concentration of phytol is 60 μg / mL.

[0282] Sample 2-32 to Sample 2-35:

[0283] Samples 2-32 to 2-35 are basically the same as sample 2-13, except for the concentration of the compound of formula (II). Therefore, the preparation method can be implemented with reference to sample 2-13.

[0284] The concentration of the compound of formula (II) in sample 2-32 was 25 μg / mL;

[0285] The concentration of the compound of formula (II) in sample 2-33 was 12 μg / mL;

[0286] The concentration of the compound of formula (II) in sample 2-34 was 6 μg / mL;

[0287] The concentration of the compound of formula (II) in sample 2-35 was 3 μg / mL.

[0288] Sample 2-36:

[0289] Sample 2-36 is essentially the same as Sample 2-12, except for the concentration of phytol. Therefore, the preparation can be made with reference to Sample 2-12. The concentration of phytol in Sample 2-36 is 60 μg / mL.

[0290] 2. Experimental Results

[0291] The experimental results are shown in Table 2.

[0292] Table 2. Cell survival rate of Experimental Example 2

[0293]

[0294] According to the experimental results, when the concentration of the compound of formula (II) is 0-50 ug / mL and the concentration of phytol is 0-60 ug / mL, there is basically no adverse effect on human immortalized keratinocytes.

[0295] <Experimental Example 3>

[0296] A control group (NC) and experimental groups 3-1 to 3-5 were set up, and human immortalized keratinocytes were treated with samples from each group. The expression level of FLG in human immortalized keratinocytes in each group was then detected by QPCR (quantitative real-time polymerase chain reaction), i.e., the relative mRNA expression level of the FLG gene.

[0297] The QPCR method can be performed according to the experimental methods described in "Molecular Biology Experimental Techniques" or "Molecular Experimental Technique Guide" or "Cell Biology Experimental Course" or "Biochemistry and Molecular Biology Experiments".

[0298] In Experimental Example 3, QPCR was performed according to the relevant method described in "Molecular Biology Experimental Techniques".

[0299] 1. Experimental samples

[0300] The samples of the control group (NC) and experimental groups 3-1 to 3-5 are NC sample, sample 3-1, sample 3-2, sample 3-3, sample 3-4, and sample 3-5, respectively, as follows:

[0301] NC samples:

[0302] Specifically, it is a cell culture medium (DMEM culture medium containing 10% FBS and 1% penicillin / streptomycin).

[0303] Sample 3-1:

[0304] Sample 3-1 is a culture solution containing the compound of formula (I), wherein the concentration of the compound of formula (I) is 12 μg / mL.

[0305] The preparation method of sample 3-1 is as follows: the cell culture medium and the compound of formula (I) are mixed to obtain sample 3-1.

[0306] Sample 3-2:

[0307] Sample 3-2 is a culture solution containing phytol, wherein the concentration of phytol is 8 μg / mL.

[0308] The preparation method of sample 3-2 is as follows: the cell culture medium and phytol are mixed to obtain sample 3-2.

[0309] Sample 3-3:

[0310] Sample 3-3 is a culture solution containing phytol, which is basically the same as sample 3-2, except that the concentration of phytol is 18 μg / mL.

[0311] Sample 3-4:

[0312] Sample 3-4 is a culture solution containing the compound of formula (I) and phytol, wherein the concentration of the compound of formula (I) is 12 μg / mL and the concentration of phytol is 8 μg / mL.

[0313] The preparation method of sample 3-4 is as follows: the cell culture medium, the compound of formula (I) and phytol are mixed to obtain sample 3-4.

[0314] Samples 3-5:

[0315] Sample 3-5 is a culture solution containing the compound of formula (I) and phytol, wherein the concentration of the compound of formula (I) is 12 μg / mL and the concentration of phytol is 18 μg / mL.

[0316] The main difference between sample 3-5 and sample 3-4 is that the concentration of phytol is 18 μg / mL. Sample 3-5 can be prepared by referring to the preparation method of sample 3-4.

[0317] 2. Experimental Results

[0318] The experimental results are detailed in Figure 9 ; Figure 9 This is a schematic diagram of the relative expression level of mRNA corresponding to each group of samples in Experimental Example 3.

[0319] from Figure 9 The results show that the combination of the compound of formula (I) and phytol can produce a synergistic effect, increasing the relative mRNA expression level of the FLG gene and promoting FLG expression. When the mass ratio of the compound of formula (I) to phytol in the sample is 12:8-18, and further, when the concentration of the compound of formula (I) is 12 μg / mL and the concentration of phytol is 8-18 μg / mL, the relative mRNA expression level of the FLG gene can be significantly increased, promoting FLG expression.

[0320] Therefore, it can be understood that when the compound of formula (I) and phytol are combined and applied to a composition, the composition can have the function of promoting the expression of FLG.

[0321] <Experimental Example 4>

[0322] A control group (NC) and experimental groups 4-1 to 4-5 were set up, and samples from each group were used to treat human immortalized keratinocytes. QPCR was then used to measure the expression of FLG in each group of immortalized human keratinocytes, i.e., the relative mRNA expression level of the FLG gene. The QPCR method can be performed according to the experimental methods described in "Molecular Biology Experimental Techniques," "Molecular Experimental Technique Guide," "Cell Biology Experimental Course," or "Biochemistry and Molecular Biology Experiments."

[0323] In Experimental Example 4, QPCR was performed according to the relevant method described in "Molecular Biology Experimental Techniques".

[0324] 1. Experimental samples

[0325] The samples of the control group (NC) and experimental groups 4-1 to 4-5 are NC sample, sample 4-1, sample 4-2, sample 4-3, sample 4-4, and sample 4-5, respectively, as follows:

[0326] NC samples:

[0327] Specifically, cell culture medium.

[0328] Sample 4-1:

[0329] Sample 4-1 is a culture solution containing the compound of formula (II), wherein the concentration of the compound of formula (II) is 12 μg / mL.

[0330] Sample 4-1 is prepared by mixing the cell culture solution and the compound of formula (II).

[0331] Sample 4-2:

[0332] Sample 4-2 is a culture solution containing phytol, wherein the concentration of phytol is 30 μg / mL.

[0333] Sample 4-2 is prepared by mixing the cell culture solution and phytol.

[0334] Sample 4-3:

[0335] Sample 4-3 is a culture solution containing phytol, which is basically the same as sample 4-2, except that the concentration of phytol is 5 μg / mL. Sample 4-3 can be prepared by referring to the preparation method of sample 4-2.

[0336] Sample 4-4:

[0337] Sample 4-4 is a culture solution containing the compound of formula (II) and phytol, wherein the concentration of the compound of formula (II) is 12 μg / mL and the concentration of phytol is 30 μg / mL.

[0338] Sample 4-4 is prepared by mixing the cell culture solution, the compound of formula (II) and phytol.

[0339] Sample 4-5:

[0340] Sample 4-5 is a culture solution containing the compound of formula (II) and phytol, wherein the concentration of the compound of formula (II) is 12 μg / mL and the concentration of phytol is 5 μg / mL.

[0341] Sample 4-5 is basically the same as sample 4-4, except that the concentration of phytol is 5 μg / mL. Sample 4-5 can be prepared by referring to the preparation method of sample 4-4.

[0342] 2. Experimental results

[0343] The experimental results are shown in Table 1. Figure 10 ; Figure 10 Figure 1 is a schematic diagram of the relative expression level of mRNA corresponding to each sample of experimental example 4.

[0344] From Figure 10The results show that when the compound of formula (II) and phytol are used together, they can produce a synergistic effect, increase the relative mRNA expression level of the FLG gene, and promote FLG expression. When the mass ratio of the compound of formula (II) to phytol in the sample is 12:5-30, and further, when the concentration of the compound of formula (II) is 12μg / mL and the concentration of phytol is 5-30μg / mL, the relative mRNA expression level of the FLG gene can be significantly increased, promoting FLG expression.

[0345] Therefore, it can be understood that when the compound of formula (II) and phytol are combined and applied to a composition, the composition can have the function of promoting the expression of FLG.

[0346] The above specific embodiments provide a detailed description of the present invention, but these do not constitute limitations of the present invention. The scope of protection of the present invention is not limited to the above embodiments. Any equivalent modifications or variations made by a person skilled in the art based on the disclosure of the present invention should be included in the scope of protection described in the claims.

Claims

1. A composition having a function of promoting the expression of filaggrin, characterized in that: include: Phytol; and Compound A; Compound A is selected from the compounds represented by formula (I) or formula (II); Formula (I): Formula (II):

2. The composition having the function of expressing filaggrin according to claim 1, characterized in that The compound A is selected from the compounds represented by formula (I), and the mass ratio of the compound represented by formula (I) to phytol is 6:(4-9).

3. The composition having the function of expressing filaggrin according to claim 1, characterized in that The compound A is selected from the compounds represented by formula (II), and the mass ratio of the compound represented by formula (II) to phytol is 12:(5-30).

4. A skin care preparation, characterized in that include: Phytol; and Compound A; Compound A is selected from the compounds represented by formula (I) or formula (II); Formula (I): Formula (II):

5. The composition having the function of expressing filaggrin according to claim 1, characterized in that Compound A is selected from the compounds represented by formula (I), and the mass ratio of the compound represented by formula (I) to phytol is 6: (4-9); or The compound A is selected from the compounds represented by formula (II), and the mass ratio of the compound represented by formula (II) to phytol is 12:(5-30).

6. Use of the composition according to claim 1 in preparing a skin care preparation.

7. Use of phytol and compound A in preparing a composition having the function of promoting filaggrin expression, wherein compound A is selected from the compounds represented by formula (I) or formula (II); Formula (I): Formula (II): The use according to claim 7, wherein the composition is used for skin care.

9. The use according to claim 7, wherein The compound A is selected from the compounds represented by formula (I), and the mass ratio of the compound represented by formula (I) to phytol is 6:(4-9).

10. The use according to claim 7, wherein The compound A is selected from the compounds represented by formula (II), and the mass ratio of the compound represented by formula (II) to phytol is 12:(5-30).

Images